Preventative Maintenance Against Viruses
Our patented dry fog system destroys enveloped and non-enveloped viruses.
The Novel Coronavirus (SARS-CoV-2) is an 'enveloped virus.' Our InstaPURE process is sufficient to denature enveloped and non-enveloped viruses like human coronavirus, H1N1, the avian flu and noroviruses. It requires little dwell time. An entire building can typically be treated in one day and provide safety for anyone concerned about getting the virus through fomite transmission.
While preventative treatment of a facility will not prevent person-to-person infections, it will help prevent surface-to-person infections.
The product we use for the first step of our pathogen protocol is on Health Canada’s list of disinfectants with evidence for use against COVID-19 (DIN 02354594) and the EPA List N: Disinfectants for Use Against SARS-CoV-2 (COVID-19). All products on this list meet EPA’s criteria for use against SARS-CoV-2, the virus that causes COVID-19.
The product we use for the second step of our pathogen protocol is currently being assessed by the EPA for inclusion on the List N. This website will be updated immediately upon confirmation.
The EPA has issued the following guidelines with respect to products that can be used to denature SARS-CoV-2:
The product should be an EPA-registered, hospital/healthcare or broad-spectrum disinfectant with directions for use on hard, porous or non-porous surfaces.
The currently accepted product label (from an EPA registered product as described above should have disinfectant efficacy claims against at least one of the following viral pathogen groupings:
a) A product should be approved by EPA to inactivate at least one large or one small non-enveloped virus to be eligible for use against an enveloped emerging viral pathogen.
b) A product should be approved by EPA to inactivate at least one small, non-enveloped virus to be eligible for use against a large, non-enveloped emerging viral pathogen.
c) A product should be approved by EPA to inactivate at least two small, non-enveloped viruses to be eligible for use against a small, non-enveloped emerging viral pathogen.